People With Lung Cancer In Clinical Trials - Prediction Markets

New York Times seeking perspectives on prediction markets/clinical trials Hi, all, My name is Rebecca Robbins, and I'm a reporter with the New York Times. I write about prescription medicines for the newspaper. You can read my bio and see my recent stories here:https://www.nytimes.com/by/rebecca-robbins I'm posting because I am hoping to hear the perspectives of people living with lung cancer for a news article I'm working on. I'm reporting on prediction markets on platforms like Kalshi and Polymarket that allow people to bet money on whether a drug will win FDA approval. Kalshiannouncedlast week that it is also planning to soon allow people to bet on whether clinical trials will succeed. Here are several prediction markets for lung cancer drug approvals that are already up and active: https://kalshi.com/markets/kxifinatamab/ifinatamab-deruxtecan/kxifinatamab-27 https://kalshi.com/markets/kxivonescimab/ivonescimab/kxivonescimab-27 https://kalshi.com/markets/kxzidesamtinib/zidesamtinib/kxzidesamtinib-27 I'm interested in hearing what people with lung cancer, and in particular those who are currently or have previously enrolled in a clinical trial, think about these prediction markets. If you're interested in being interviewed for this story, you can reach me at 714-478-4224 [email redacted]. From there, we'll set up a phone or video interview. For this article, I'm hoping to speak with people who are comfortable with potentially being quoted in the newspaper using their full name. And beyond this story, I'd also like to hear from you if you have a suggestion for another issue in lung cancer that you think the New York Times should be writing about. Thank you for considering.